Markets/FDA approves Axsome Therapeutics' AXS-05?

FDA approves Axsome Therapeutics' AXS-05?

Market Price

82%YES

18%NO

Vol 24h$1K

Liquidity$2K

Bid / Ask65% / 98%

Spread32.70pp

ClosesApr 30, 2026

✦ Deep AI Analysis🔒 PRO

The market's precipitous 15pp decline over seven trading sessions reflects mounting uncertainty around the diplomatic timeline. Cross-venue signals show institutional venues pricing 6pp below Polymarket.

The FM model flags a structural overpricing: with less than 10 days to expiry and no confirmed diplomatic channel active, the Bayesian update pushes the model estimate well below current market price. Three correlated outcome markets collectively imply only a 23% chance any deadline resolves YES.

Watch for: official bilateral statements, foreign ministry press briefings, and whether the longer-dated outcome markets begin to converge as a leading indicator of changed expectations.

Synthesizes price, cross-venue gaps, Bayesian edge, and event context into a concise brief.

✦ Unlock with Pro

Wikipedia Attention

Price History · 30 days

Export CSV

Price History

MarketFM Estimate

-6.7pp

Research Summary

Prediction markets currently price "FDA approves Axsome Therapeutics' AXS-05?" at 82% YES / 18% NO. In the last 24 hours, $1K has been traded. A Bayesian estimate puts the probability at 82%. The bid-ask spread is 32.70pp. The market closes on April 30, 2026.

Cite this snapshot

ForecastMind (2026-04-26). "FDA approves Axsome Therapeutics' AXS-05?." Prediction market snapshot: YES 82%, NO 18%. Retrieved from https://forecastmind.org/markets/2036695